Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VTRS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Tyrvaya | Dry Eye | N/A · NCT07705893 | Recruiting |
| Treatment with 137 µg azelastine hydrochloride… | Allergic Rhinitis Due to Allergens | Phase 4 · NCT07597473 | Completed |
| Revefenacin | COPD Exacerbation | Phase 4 · NCT07721922 | Not yet recruiting |
| Oxycodone | Healthy | Phase 4 · NCT07813026 | Recruiting |
| Tramadol | Acute Pain | Phase 3 · NCT06215859 | Completed |
| Deoxycholate Amphotericin B (DAmB) | Talaromycosis | Phase 3 · NCT06525389 | Not yet recruiting |
| Pimecrolimus 0.3% Ophthalmic Ointment | Blepharitis | Phase 3 · NCT06400511 | Terminated |
| phentolamine ophthalmic solution 0.75%, a… | Mesopic Vision | Phase 3 · NCT06349759 | Completed |
| MR-107A-02 | Acute Pain | Phase 3 · NCT06215859 | Completed |
| Liposomal Amphotericin B | Talaromycosis | Phase 3 · NCT06525389 | Not yet recruiting |
| Cenerimod | Nephritis, Lupus | Phase 3 · NCT07201129 | Recruiting |
| Bedaquiline | MDR-TB | Phase 3 · NCT07486024 | Recruiting |
| Selatogrel | Acute Myocardial Infarction | Phase 2 · NCT03487445 | Completed |
| AC-076 for s.c. administration | Healthy Subjects | Phase 1 · NCT03173625 | Completed |
| ACT-334441 2 mg | Healthy Subjects | Phase 1 · NCT02479204 | Terminated |
| Ethinyl Estradiol | Healthy Subjects | Phase 1 · NCT04255277 | Completed |
Also used in these trials (approved or third-party drugs, not VTRS's own candidates): Gabapentin, Varenicline, Sildenafil, Ipratropium Bromide, Formoterol Fumarate, Albuterol Sulfate, Alprazolam, Flucytosine, Rifampicin, Ticagrelor, Clopidogrel Bisulfate, Atenolol.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VTRS holds $1.8B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VTRS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 126,764,446 | 11.06% | 2026-08-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 84,807,083 | 7.40% | 2026-03-31 |
| DAVIS SELECTED ADVISERS | Institution (13G, 5%+) | 72,403,329 | 6.32% | 2026-09-30 |
| Scott Andrew Smith Chief Executive Officer, Director · +1.56M options |
Insider | 1,329,326 | 0.12% | 2026-03-06 |
| Paul Campbell Officer · +229,185 options |
Insider | 316,530 | 0.03% | 2026-06-25 |
| Andrew Enrietti Chief Administrative and Transformation · +162,894 options |
Insider | 234,444 | 0.02% | 2026-08-15 |
| Melina E Higgins Director · +15,890 options |
Insider | 220,048 | 0.02% | 2026-03-06 |
| Mark W Parrish Director · +15,890 options |
Insider | 165,230 | 0.01% | 2026-03-06 |
| James M Kilts Director · +15,890 options |
Insider | 161,257 | 0.01% | 2026-03-06 |
| Richard A Mark Director · +15,890 options |
Insider | 116,145 | 0.01% | 2026-03-06 |
| W Don Cornwell Director · +15,890 options |
Insider | 112,044 | 0.01% | 2026-03-06 |
| Goff Corinne Le Chief Commercial Officer |
Insider | 107,135 | 0.01% | 2026-04-15 |
Share count 1,146,454,729 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VTRS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →